Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky. The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates ...

Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has ​signed an exclusive global licensing deal ‌with ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing ...

Sino Biopharm grants global rights of its blood cancer drug to Sanofi for up to $1.53 billion, including $135M upfront and ...

A phase III trial found that combining giredestrant with Pfizer’s Ibrance did not significantly slow disease progression compared with standard ...

Cipla USA has recalled over 400 cartons of Nilotinib Capsules used to treat blood cancers after they failed to meet specifications, according to the U.S. Food and Drug Administration, which classified ...

Cipla recalls over 400 cartons of Nilotinib cancer medication in the U.S. due to manufacturing specification issues, USFDA reports.

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.

Frankfurt: Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising breast cancer drug candidate giredestrant can help newly diagnosed patients.At ...